AIxCrypto Launches AIxC Hub, Attracts Over 200,000 Registered Users
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: PRnewswire
- User Engagement Surge: Since its launch on January 7, AIxC Hub has attracted over 200,000 registered wallet addresses, reflecting strong early user adoption that is expected to drive rapid ecosystem growth.
- Active User Growth: As of January 11, the platform recorded 163,762 active participants, indicating high user engagement in market simulation and educational activities, which further enhances AIxCrypto's market influence.
- Social Media Interaction: Within the first 48 hours of launch, AIxC-related content generated over 3 million social media impressions, demonstrating strong marketing effectiveness that helps boost brand awareness and user retention.
- Global Market Expansion: By collaborating with over 160 key opinion leaders, AIxCrypto has successfully established early community presence in Vietnam, Korea, and China, with plans to expand into Brazil and Europe, further strengthening its global market positioning.
Analyst Views on AIXC
About AIXC
AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
